Back to Search Start Over

Multifunctionality of Calebin A in inflammation, chronic diseases and cancer.

Authors :
Brockmueller A
Mueller AL
Kunnumakkara AB
Aggarwal BB
Shakibaei M
Source :
Frontiers in oncology [Front Oncol] 2022 Sep 16; Vol. 12, pp. 962066. Date of Electronic Publication: 2022 Sep 16 (Print Publication: 2022).
Publication Year :
2022

Abstract

Chronic diseases including cancer have high case numbers as well as mortality rates. The efficient treatment of chronic diseases is a major ongoing medical challenge worldwide, because of their complexity and many inflammatory pathways such as JNK, p38/MAPK, MEK/ERK, JAK/STAT3, PI3K and NF-κB among others being implicated in their pathogenesis. Together with the versatility of chronic disease classical mono-target therapies are often insufficient. Therefore, the anti-inflammatory as well as anti-cancer capacities of polyphenols are currently investigated to complement and improve the effect of classical anti-inflammatory drugs, chemotherapeutic agents or to overcome drug resistance of cancer cells. Currently, research on Calebin A, a polyphenolic component of turmeric ( Curcuma longa ), is becoming of growing interest with regard to novel treatment strategies and has already been shown health-promoting as well as anti-tumor properties, including anti-oxidative and anti-inflammatory effects, in diverse cancer cells. Within this review, we describe already known anti-inflammatory activities of Calebin A via modulation of NF-κB and its associated signaling pathways, linked with TNF-α, TNF-β and COX-2 and further summarize Calebin A's tumor-inhibiting properties that are known up to date such as reduction of cancer cell viability, proliferation as well as metastasis. We also shed light on possible future prospects of Calebin A as an anti-cancer agent.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Brockmueller, Mueller, Kunnumakkara, Aggarwal and Shakibaei.)

Details

Language :
English
ISSN :
2234-943X
Volume :
12
Database :
MEDLINE
Journal :
Frontiers in oncology
Accession number :
36185259
Full Text :
https://doi.org/10.3389/fonc.2022.962066